before financing costs and income tax expense 44.92 28.18 45.36 17.91 35.00 33.60 65.09 24.86 (0.44) (0.97) Financing cost 8.69 5.45 3.96 1.56 11.08 10.64 9.95 3.80 4.73 119.44 Profit before income tax
performance Unit: Million Baht 2017 2016 Sales 2,055.79 1,576.09 Cost of Sales 1,844.15 1,479.34 Gross Margin 211.64 96.75 Gain (loss) on exchange rates 21.92 5.17 Other Incomes 19.91 19.09 Total Revenues
items) 788.08 100.0% 848.81 100.0% 831.82 100.0% -2.0% 5.6% Cost of services (604.39) -76.7% (664.22) -78.2% (655.73) -78.8% -1.3% 8.5% Gross profit 183.69 23.3% 184.59 21.8% 176.09 21.2% -4.6% -4.1
(0.24) million due to most customers in the government sector changing their bidding process to E-bidding which has lower cost and expense. (Unit : Million Baht) 2018 2017 Change % Change Revenue from
3.99% Selling & Administrative Expenses 140.62 196.61 (55.99) (28.48%) Finance Cost 39.52 42.66 (3.14) (7.36%) EBT 165.92 (2.15) 168.06 7,819.16% Tax (24.83) 8.98 33.81 376.55% Total Comprehensive Income
. Because the business has more intense competition as a result the unit price to decrease and the baht appreciation and also has an effect from the increased cost-to-income ratio. SG&A SG&A of the Company
and total portfolio and a strong growth of both domestic and overseas subsidiaries. In addition, the Company efficiently managed the selling, general and administrative expense and funding cost. 2
for sales staff, traveling and vehicle expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and
expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of the Company’s